Lymphoma
BGB-11417-303
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial overview
Clinical Area
Haematology
Disease
Lymphoma
Disease site
Malignant Haematology
Study Phase
III
Trial Identifiers
Registration number: NCT06943872
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries